ITGA2
Basic information
Region (hg38): 5:52989340-53094779
Previous symbols: [ "CD49B" ]
Links
Phenotypes
GenCC
Source:
- platelet-type bleeding disorder 9 (Strong), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ITGA2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 16 | 25 | ||||
missense | 54 | 14 | 15 | 83 | ||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 4 | 3 | 7 | |||
non coding | 74 | 26 | 99 | 199 | ||
Total | 0 | 0 | 133 | 46 | 130 |
Variants in ITGA2
This is a list of pathogenic ClinVar variants found in the ITGA2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-52989345-G-A | Platelet-type bleeding disorder 9 | Benign (Jun 20, 2021) | ||
5-52989370-G-C | Platelet-type bleeding disorder 9 | Uncertain significance (Jun 14, 2016) | ||
5-52989380-T-A | Platelet-type bleeding disorder 9 | Uncertain significance (Jan 13, 2018) | ||
5-52989434-C-T | Platelet-type bleeding disorder 9 | Uncertain significance (Jan 13, 2018) | ||
5-52989456-G-A | Platelet-type bleeding disorder 9 | Benign (Jan 13, 2018) | ||
5-52989479-A-G | Platelet-type bleeding disorder 9 | Benign (Jan 12, 2018) | ||
5-52989482-G-C | Inborn genetic diseases | Uncertain significance (Sep 06, 2022) | ||
5-52989493-G-T | Inborn genetic diseases | Likely benign (Feb 27, 2024) | ||
5-52989502-C-A | Inborn genetic diseases | Uncertain significance (May 28, 2024) | ||
5-52989814-G-GCA | Benign (Jun 19, 2021) | |||
5-52989814-G-GCACA | Benign (Jun 19, 2021) | |||
5-52989833-CACAG-C | Benign (Jun 19, 2021) | |||
5-52989837-G-C | Benign (Nov 12, 2018) | |||
5-53026539-G-A | Benign (Jun 21, 2021) | |||
5-53026768-G-A | Uncertain significance (Sep 03, 2019) | |||
5-53026806-C-T | Platelet-type bleeding disorder 9 | Benign (Jan 12, 2018) | ||
5-53026854-T-A | Platelet-type bleeding disorder 9 • Inborn genetic diseases | Uncertain significance (Dec 26, 2023) | ||
5-53026866-C-A | Inborn genetic diseases | Uncertain significance (Mar 08, 2024) | ||
5-53026878-T-C | Platelet-type bleeding disorder 9 • ITGA2-related disorder | Uncertain significance (Jan 12, 2018) | ||
5-53026891-G-T | Benign (Nov 12, 2018) | |||
5-53027152-T-TGATA | Benign (Nov 12, 2018) | |||
5-53041926-A-G | Benign (Nov 12, 2018) | |||
5-53041953-T-C | Benign (Nov 12, 2018) | |||
5-53042078-C-T | Benign (Nov 12, 2018) | |||
5-53042138-G-A | Inborn genetic diseases | Uncertain significance (Jan 04, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ITGA2 | protein_coding | protein_coding | ENST00000296585 | 30 | 105454 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.28e-11 | 1.00 | 125580 | 0 | 168 | 125748 | 0.000668 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.854 | 549 | 608 | 0.903 | 0.0000301 | 7766 |
Missense in Polyphen | 176 | 220.78 | 0.79719 | 2886 | ||
Synonymous | -0.768 | 234 | 220 | 1.07 | 0.0000115 | 2234 |
Loss of Function | 4.27 | 29 | 66.6 | 0.435 | 0.00000358 | 779 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000832 | 0.000832 |
Ashkenazi Jewish | 0.000397 | 0.000397 |
East Asian | 0.000655 | 0.000653 |
Finnish | 0.000555 | 0.000554 |
European (Non-Finnish) | 0.000762 | 0.000756 |
Middle Eastern | 0.000655 | 0.000653 |
South Asian | 0.000949 | 0.000948 |
Other | 0.000329 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix.; FUNCTION: (Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for Human echoviruses 1 and 8. {ECO:0000269|PubMed:8411387}.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Platelet activation - Homo sapiens (human);ECM-receptor interaction - Homo sapiens (human);Focal adhesion - Homo sapiens (human);Dilated cardiomyopathy (DCM) - Homo sapiens (human);Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human);Small cell lung cancer - Homo sapiens (human);Phagosome - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hematopoietic cell lineage - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Platelet Aggregation Inhibitor Pathway, Pharmacodynamics;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Integrin-mediated Cell Adhesion;Arrhythmogenic Right Ventricular Cardiomyopathy;Interleukin-11 Signaling Pathway;Human Complement System;Focal Adhesion;TGF-beta Signaling Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Ebola Virus Pathway on Host;Ebola Virus Pathway on Host;Developmental Biology;Signal Transduction;Integrin cell surface interactions;Laminin interactions;Extracellular matrix organization;Platelet Adhesion to exposed collagen;Integrin;CHL1 interactions;Hemostasis;VEGFR3 signaling in lymphatic endothelium;Arf6 trafficking events;L1CAM interactions;Syndecan interactions;Plexin-D1 Signaling;Non-integrin membrane-ECM interactions;Axon guidance;ECM proteoglycans;MET activates PTK2 signaling;MET promotes cell motility;Signaling by MET;Signaling by Receptor Tyrosine Kinases;Beta1 integrin cell surface interactions;Syndecan-2-mediated signaling events
(Consensus)
Recessive Scores
- pRec
- 0.624
Intolerance Scores
- loftool
- 0.501
- rvis_EVS
- -0.24
- rvis_percentile_EVS
- 36.32
Haploinsufficiency Scores
- pHI
- 0.278
- hipred
- N
- hipred_score
- 0.463
- ghis
- 0.444
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.847
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Itga2
- Phenotype
- integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; hematopoietic system phenotype;
Gene ontology
- Biological process
- response to hypoxia;positive regulation of leukocyte migration;substrate-dependent cell migration;hypotonic response;cell adhesion;cell-matrix adhesion;integrin-mediated signaling pathway;female pregnancy;blood coagulation;cell population proliferation;animal organ morphogenesis;positive regulation of epithelial cell migration;positive regulation of alkaline phosphatase activity;response to amine;response to muscle activity;positive regulation of smooth muscle cell migration;extracellular matrix organization;mammary gland development;positive regulation of cell projection organization;cell-substrate adhesion;positive regulation of collagen biosynthetic process;positive regulation of collagen binding;response to L-ascorbic acid;cell adhesion mediated by integrin;collagen-activated signaling pathway;response to drug;positive regulation of DNA binding;skin morphogenesis;establishment of protein localization;positive regulation of translation;positive regulation of cell adhesion;positive regulation of smooth muscle contraction;viral entry into host cell;focal adhesion assembly;mesodermal cell differentiation;positive regulation of smooth muscle cell proliferation;positive regulation of inflammatory response;positive regulation of positive chemotaxis;detection of mechanical stimulus involved in sensory perception of pain;positive regulation of transmission of nerve impulse;positive regulation of phagocytosis, engulfment;hepatocyte differentiation;response to parathyroid hormone;cellular response to mechanical stimulus;cellular response to estradiol stimulus
- Cellular component
- nucleus;plasma membrane;focal adhesion;integrin complex;external side of plasma membrane;cell surface;integrin alpha2-beta1 complex;axon terminus;basal part of cell;perinuclear region of cytoplasm
- Molecular function
- amyloid-beta binding;virus receptor activity;integrin binding;protein binding;collagen binding;collagen receptor activity;laminin binding;heparan sulfate proteoglycan binding;protein-containing complex binding;metal ion binding;protein heterodimerization activity;collagen binding involved in cell-matrix adhesion